Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedländer, Éric Pujade-Lauraine, Val Gebski et al.|The Lancet Oncology|2018Cited by 137
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group studyLari Wenzel, Marion Piedmonte, Paul K. J. Han et al.|Gynecologic Oncology|2017Cited by 25
“She Was a Little Social Butterfly”: A Qualitative Analysis of Parent Perception of Social Functioning in Adolescent and Young Adult Brain Tumor SurvivorsJustin Wilford, Lari Wenzel, David Buchbinder et al.|Journal of Pediatric Oncology Nursing|2017Cited by 22
Quality of Life Among Parents of Adolescent and Young Adult Brain Tumor SurvivorsDavid Buchbinder, Lari Wenzel, Leonard S. Sender et al.|Journal of Pediatric Hematology/Oncology|2017Cited by 21
Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.Michael Friedländer, Éric Pujade-Lauraine, Val Gebski et al.|Journal of Clinical Oncology|2017Cited by 18